Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 3,781 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 2 Diabetes Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

NCT03387657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Hydrochlorothiazide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 30, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cooking Health-Oriented Meals to Prevent Dementia and Diabetes

NCT07661368
View directory record Official record
Conditions
Type 2 Diabetes, Dementia
Interventions
Cooking skills training including in-person classes, Cooking skills education (at-home)
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

NCT02211261
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-06293620, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Chula Vista, California • DeLand, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Not applicable Interventional Results available

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

NCT00232583
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Insulin, Metfomin, Pioglitazone, glyburide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 30, 2026, 9:34 PM EDT
Recruiting Phase 3 Interventional

RCT Glargine vs NPH for Treatment of DM in Pregnancy

NCT06619301
View directory record Official record
Conditions
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions
Insulin glargine, insulin NPH
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes

NCT01076829
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Spice polyphenols
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

NCT02682901
View directory record Official record
Conditions
Diabetic Autonomic Neuropathy
Interventions
Cycloset, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo-matching dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
164
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

NCT00873223
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

NCT02383940
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 30, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional

Enhancing Digitally Delivered Diabetes Education With Real-Time CGM

NCT06296550
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Dulce Digital Text Messaging Intervention, CGM Device
Other
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence

NCT02955238
View directory record Official record
Conditions
Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
40 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 30, 2026, 9:34 PM EDT
Completed No phase listed Observational

Validation of a CREATION Health Assessment Tool for Patients in a Diabetic Outpatient Population

NCT03686917
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
CHAT-P
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Blood Glucose Awareness Training for Parents

NCT00315991
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Blood Glucose Awareness Training for Parents
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 11 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 30, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional

Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes

NCT05933174
View directory record Official record
Conditions
Type2diabetes
Interventions
Prompt-sheet, Usual education
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
45 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 30, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes

NCT05208164
View directory record Official record
Conditions
Type 2 Diabetes, Sleep, Stress
Interventions
Mindfunlness Meditation
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Electronic Alerts for Heart Failure Prevention in Diabetes

NCT04791826
View directory record Official record
Conditions
Heart Failure, Diabetes Mellitus, Type 2
Interventions
On-screen electronic alert
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 30, 2026, 9:34 PM EDT
Withdrawn Phase 3 Interventional

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

NCT00754689
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Metformin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

NCT03058289
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Bile Duct Cancer, Chordoma of Sacrum, Sarcoma
Interventions
INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Drug · Biological
Lead sponsor
Intensity Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

NCT01789788
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6811135
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Chula Vista, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

NCT04660643
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Pelham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 30, 2026, 9:34 PM EDT
Recruiting Early Phase 1 Interventional

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

NCT05041491
View directory record Official record
Conditions
Pre-diabetes
Interventions
BREAK, ONE
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 30, 2026, 9:34 PM EDT
Withdrawn No phase listed Observational

Mitigation of Type 2 Diabetes by Partial Ileal Bypass

NCT02493374
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 30, 2026, 9:34 PM EDT